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Abstract: In the current study, we introduce an integrative machine learning strategy for the autonomous molecular design of protein kinase inhibitors using variational autoencoders and a novel
cluster-based perturbation approach for exploration of the chemical latent space. The proposed strategy combines autoencoder-based embedding of small molecules with a cluster-based perturbation
approach for efficient navigation of the latent space and a feature-based kinase inhibition likelihood
classifier that guides optimization of the molecular properties and targeted molecular design. In the
proposed generative approach, molecules sharing similar structures tend to cluster in the latent space,
and interpolating between two molecules in the latent space enables smooth changes in the molecular
structures and properties. The results demonstrated that the proposed strategy can efficiently explore
the latent space of small molecules and kinase inhibitors along interpretable directions to guide the
generation of novel family-specific kinase molecules that display a significant scaffold diversity and
optimal biochemical properties. Through assessment of the latent-based and chemical feature-based
binary and multiclass classifiers, we developed a robust probabilistic evaluator of kinase inhibition
likelihood that is specifically tailored to guide the molecular design of novel SRC kinase molecules.
The generated molecules originating from LCK and ABL1 kinase inhibitors yielded ~40% of novel
and valid SRC kinase compounds with high kinase inhibition likelihood probability values (p > 0.75)
and high similarity (Tanimoto coefficient > 0.6) to the known SRC inhibitors. By combining the
molecular perturbation design with the kinase inhibition likelihood analysis and similarity assessments, we showed that the proposed molecular design strategy can produce novel valid molecules
and transform known inhibitors of different kinase families into potential chemical probes of the
SRC kinase with excellent physicochemical profiles and high similarity to the known SRC kinase
drugs. The results of our study suggest that task-specific manipulation of a biased latent space may
be an important direction for more effective task-oriented and target-specific autonomous chemical
design models.

Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.

Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

Keywords: autonomous molecular design; deep learning models; latent space landscapes; protein
kinases; kinase inhibitors; perturbation chemical modeling; kinase inhibition likelihood classifiers;
explainable machine learning

1. Introduction
The recent advances in machine learning (ML) have driven the design of new expert
systems and automated workflows capable of modeling complex chemical and biological phenomena [1–5]. Generative deep learning models are often used for navigating
an enormous chemical space of small molecules and molecular design [6–8]. Numerous
generative-based approaches employing different neural network architectures, molecular representations, and analysis metrics have been developed and deployed in recent
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years, leading to significant progress in enabling autonomous molecular design. Deep
neural network (DNN) models, such as variational autoencoders (VAE) [9], have been
particularly useful in the molecular design of novel chemical probes. VAEs are a special
type of autoencoders’ neural networks that compress molecular space into a continuous
vector space representation. In this approach, the encoded data points are sampled from
multidimensional statistical distribution and are then fed into the decoder that reconstructs
the original input molecules. The objective function used for training includes a term
penalizing reconstruction error and a term constraining the encoded parameters to be close
to a normal distribution, which in turn facilitates proper sampling of the latent space [9].
Chemical variational autoencoder (ChemVAE) is a deep learning framework that converts
discrete representations of molecules to and from a multidimensional continuous representation, enabling the generation of new molecules for efficient exploration and optimization
via open-ended chemical spaces [9]. In this approach, the VAE is trained jointly with
a model for property prediction that include the quantitative estimate of druglikeness
(QED) [10], synthetic accessibility score (SAS) [11], and water–octanol partition coefficient
(logP) [12]. This architecture ensures a smooth and continuous representation of both
chemical structures and biochemical properties, which facilitates navigation in the latent
space and the design of novel molecules with the desired properties.
Generative adversarial networks (GAN) represent another class of ML approaches
successfully applied for de novo molecular design [13–18]. GANs are defined by a pair
of neural networks, a generator, and a discriminator, trained in competition with each
other. An approach termed LatentGAN combines an autoencoder and a generative adversarial neural network for de novo molecular design [14]. Another approach DruGAN
integrates GAN and VAE architectural frameworks by training an adversarial autoencoder to efficiently sample molecules from the latent space [15]. MolGAN is an implicit
generative model for molecular graphs that circumvents the need for expensive graph
matching procedures and adapts the GAN approach to operate directly on graph-structured
data [17]. The MolCycleGAN approach employs cycle-consistent adversarial networks to
learn transformation rules between sets of compounds with desired and undesired values
of the considered property [18]. The progress in GAN applications to molecular discovery
has been further catalyzed by the development of several comprehensive benchmarking
sets and cheminformatics’ infrastructure [19,20]. These validation platforms can evaluate
the diversity and quality of the generated molecules by measuring the fidelity of GAN
models in reproducing the property distribution of the training sets and assessing the
ability to generate valid novel molecules for the goal-oriented and target-specific molecule
generation processes.
Generative-based ML models that enable the generation of a three-dimensional (3D)
representation of small molecules have also received considerable attention for their unique
advantages and potential to explicitly design drug-like molecules in a target-conditioning
manner [21]. A novel molecular deep generative model adopts a recurrent neural network architecture coupled with a ligand–protein interaction fingerprint as constraints [22].
DeepLigBuilder is a novel deep learning-based method for de novo drug design that
combines a graph-based generative model for the design of chemically and conformationally valid molecules with a Monte Carlo tree search to optimize the molecular and
structural parameters [23]. A comprehensive review of generative models categorizes them
into three types, depending on featurization of the 3D representation of small molecules:
cubic grid-based, Euclidean distance matrix (EDM)-based, and Cartesian coordinate-based,
where each type of featurization requires distinct generative architectures and optimization
strategies [24]. Attention-based generative models for de novo molecular design offer new
architectures that enable a more accurate sampling from the latent space and exploration
of novel chemistry space not present in the training data [25]. Efficient multiobjective
molecular design approaches combine in silico prediction of molecular property-defined
desirability ranges and substructure constraints with particle swarm optimization for effective navigation in a continuous latent space [26–29]. The performances of various VAE and
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GAN models are typically evaluated based on goal-directed tasks (rediscovery, optimization, and scaffold hopping of active compounds) and target-specific objectives (generation
of novel compounds for a given target) [30]. Various ML methods such as Extreme Gradient
Boosting (XGBoost) [31], DNN models [32], and graph-based attention models [33] are
applied to predict the selectivity of small molecules towards the proteins that belong to the
same family. An extensive comparative analysis of the predictive capacity of the classical
feature-based models (SVM, XGBoost, RF, and DNN) and four different graph-based neural
network models has demonstrated a superior performance and exceptional computational
efficiency of the XGBoost and RF methods [34]. By learning molecular descriptors and
fingerprint features of over 8 million small molecules, a new feature-generation convolutional neural network (CNN) approach MolMap has outperformed existing ML models on
several relevant benchmark datasets [35].
ML models have been actively deployed to help in the discovery of novel inhibitors
targeting protein kinases, which are important oncology targets [36,37]. The generative
tensorial reinforcement learning (GENTRL) approach has proposed a VAE model that compresses the space of small molecule structures onto the latent space in a high-dimensional
lattice followed by exploration and optimization by reinforcement learning to discover
novel kinase inhibitors [38]. A computational approach combining fragment-based design
and deep generative modeling augmented by three-dimensional pharmacophore screening
has been proposed for the systematic design of covalent protein kinase inhibitors [39].
ML models have shown the ability to distinguish between multitarget and single-target
kinase inhibitors [40] as well as robust performance in predicting different chemical classes
of kinase inhibitors [41]. By representing kinase inhibitors as a large number of molecular
descriptors, feature-based ML models can provide an accurate classification of kinase
probes according to their binding modes [42].
The design of novel and selective chemical probes to interrogate kinase functions
remains a considerable challenge. The objective of the current investigation is the development and validation of an integrated ML approach for the autonomous molecular design
of chemical probes for protein kinase target-specific tasks. Proto-oncogene tyrosine-protein
kinase SRC (short for sarcoma) is a non-receptor tyrosine kinase protein that plays a vital
role in regulating diverse cellular processes and is frequently overexpressed in various
cancers [43]. We develop and implement a perturbation-based deep learning approach
for the guided chemical transformation of small molecules and generic kinase molecules
into potential chemical probes of SRC kinase. The proposed strategy combines ChemVAE
embedding architecture with cluster decomposition and perturbation-based exploration
of the continuous latent space to facilitate sampling along the interpretable controllable
directions and allow for the efficient molecular design of specific chemical probes. The important feature of this generative approach is that molecules sharing similar structures
tend to cluster in the latent space and interpolating between two molecules in the latent
space could lead to smooth changes in the molecular structures and properties. Another
advantage of the cluster-based perturbation strategy is a guided control over the navigation of the latent space that can increase both the performance and interpretability of the
design predictions. A robust chemical feature-based machine learning predictor of the
kinase inhibition likelihood is introduced to aid in the perturbation-based transformation
of small molecules. By combining molecular perturbation design with the kinase inhibition
likelihood analysis and similarity assessments, we demonstrate that the proposed strategy
can morph kinase inhibitors into novel chemical probes of the SRC kinase that exhibit
desirable ranges for all included chemical properties and similarity to the known potent
SRC kinase inhibitors.
2. Results and Discussion
2.1. Integrative Machine Learning Model for Targeted Exploration of the Chemical Space
We began by introducing the proposed ML model and describing the components
and main stages of the generative molecular design pipeline (Figure 1). The approach
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synergistically combined the following modules: (A) data mining and latent space analysis
of small molecules and kinase inhibitors; (B) ChemVAE embedding of small molecules into
the latent space; (C) clustering of molecule-specific embeddings; (D) cluster-based perturbation approach for efficient navigation of the continuous latent space; and (E) feature-based
5 of 23
kinase inhibition likelihood classifier to guide optimization of the molecular properties and
targeted exploration of the latent space (Figure 1).
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(C) cluster-based and perturbation-driven controlled navigation of the latent space along interdirections, (D) kinase inhibition likelihood classifier, and (E) cheminformatics-based analysis of
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database release of over 230 million compounds in ready-to-dock, 3D formats [48]. For
datasets of kinase chemical probes, we used (a) ~20,000 known kinase inhibitors
representing 10 major kinase families SRC, ABL1, CSF1R, EGFR, FLT3, KDR, LCK,
MAPK10, MAPK14, and MET that were obtained from the ZINC15 database [48]; and (b)
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230 million compounds in ready-to-dock, 3D formats [48]. For datasets of kinase chemical
probes, we used (a) ~20,000 known kinase inhibitors representing 10 major kinase families
SRC, ABL1, CSF1R, EGFR, FLT3, KDR, LCK, MAPK10, MAPK14, and MET that were
obtained from the ZINC15 database [48]; and (b) a dataset of competitive and allosteric
protein kinase inhibitors confirmed by X-ray crystallography [49]. We also leveraged the
size and synthetic feasibility of the GDB-17 [50] and FDB-17 [51] enumerated datasets of
small molecules. For computational reasons, we utilized the GDB-17 lead set (~11 million
compounds) and FDB-17 subset (~10 million molecules) selected from GDB-17 by applying
fragment-likeness criteria and complexity reduction filters. The GDB-17 dataset has the
most uniform distribution for the distinct chemical categories (heteroaromatic, aromatic,
heterocyclic, carboxylic, acyclic) and provided an exceptionally high quality, large set of
random small molecules to serve as a baseline for molecular generation experiments.
An adaptation of the ChemVAE approach [9] was used for the embedding of small
molecules into the latent space (Figure 1). An important component of the proposed
methodology comes from a non-trivial targeted utilization of the ChemVAE framework that
generates latent landscapes for small molecules and kinase inhibitors. This strategy enabled
the model to generate more accurate and informative latent spaces while allowing for
control over a modelled distribution. By performing cluster-based perturbation in the latent
representation of the molecules, the generative design approach encouraged ChemVAE
to explore the high-density distinct areas of the latent space for molecule generation,
while also facilitating morphing of the kinase molecules from different families into SRC
kinase-specific chemical probes (Figure 1). In this approach, the properties of generated
molecules were controlled by sampling latent representations along linear interpretable
directions that optimize the kinase inhibition likelihood metric. Based on the latent space
analysis, it was assumed that molecules with similar structures would tend to cluster
together in the latent space and that interpolating two molecules x1 and x2, represented
by latent vectors z1 and z2, could lead to the intermediate molecules representing gradual
transformation from molecule x1 to molecule x2. Given that molecular structures of
small molecules generally have a tendency to correlate with their respective molecular
properties, these assumptions implied that molecules with comparable properties would
cluster together and interpolating between the two molecules with different values of the
molecular property could lead to gradual changes in the molecular structures and property
profiles of generated molecules.
After evaluating the optimal parameters, we examined each stage of the generative
learning process and monitored the number of produced valid molecules when the chemical
transformation was initiated from different kinase families (Figure 1). Several quantitative
metrics assessed whether a combination of clustering and perturbation-based targeted
exploration of the latent space could allow for efficient chemical transformation of the
existing kinase inhibitors from different families into SRC chemical probes. We evaluated
similarity between the generated novel molecules and known potent SRC kinase inhibitors.
In addition, the main physicochemical properties of generated chemical probes were
evaluated at the last stage of the process (Figure 1). Through this analysis, the chemical
feasibility and property profiles of designed kinase probes were examined in greater detail.
2.2. Principal Component Analysis of the Latent Space Landscapes for Small Molecules and
Kinase Inhibitors
Using ChemVAE, the training sets of GDB-17 molecules and kinase inhibitors were
encoded into a 196-dimensional vectorial representation in the continuous latent space.
The 196-dimensional vectors representing these molecules were then fed through principal
component analysis (PCA) to facilitate visualization and analysis of the latent space in
two dimensions (Figure 2). For the latent space analysis, we employed a sample of the
GDB-17 database corresponding to 163,953 random small molecules from a variety of
domains, with the following atoms (C, N, O, S, F, Cl, Br, P, I) [50,51]. The set of kinase
inhibitors included 1883 unique ABL1 kinase inhibitors and 3477 unique SRC kinase
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inhibitors. The chemical properties for these molecules were calculated using RDKit
software (release 2022.03.1, T5 Informatics GmbH, Basel, Switzerland) for chemical7 of
data
23
analysis [52]. The composite data included molecules with a molecular weight less than
700 Daltons, calculated logP < 6, and fewer than 10 rotatable bonds.
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PCA allowed to reduce the dimensionality of the dataset while still preserving most
of the variance by creating a new feature space based on the top eigenvectors. By computing the percentage of variance explained by the individual principal components (PCs),
we found that a significant amount of variance in the data samples and the topology of the
latent space landscape could be accounted for by the first two PCs (Figure 3). We observed
that significant information of the data was accounted for by the principal components.
For PCA of the latent space of the kinase molecules and GDB-17 small molecules dataset
(Figure 3A), PC-1 accounts for 36.79% of variance and PC-2 accounts for 24.14% of the
variance. For PCA of the latent space for the kinase inhibitors, PC-1 accounts for 44.92%
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of variance and PC-2 accounts for 33.63% of the variance. The high dimensionality of the
dataset may be responsible for the observed percentages of variances as higher dimensionality introduces more variability and randomness. Therefore, we performed a statistical
analysis of the dataset to assist in the visual analysis of the latent space. In particular, to aid
in the analysis of the kinase molecules in the latent space, we calculated statistical measures
including the general range, the range of the centroid vector, and the range of the standard
deviation vector for each kinase family (Table S1). We found that each kinase family covered
a similar minimum and maximum value in the encoded space, with all families occupying
the same critical region of the latent space. These observations reinforced the notion that
the encoded representations of the kinase molecules shared important chemical and functional characteristics common for molecules binding to kinase targets. The locations of the
Int. J. Mol. Sci. 2022, 23, 11262
kinase molecules in the latent space corresponded to representations of specific chemical or
molecular properties in those regions.
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that significant information of the data was accounted for by the principal components. For
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The minimum standard deviation values were in the range of 0.65–0.86, while the
maximum standard deviation values were within 1.29–1.63 (Table S1). The SRC kinase
inhibitors were characterized by the largest minimum and maximum standard deviation
values, which was reflected in a large distribution spread of the latent space region populated by these kinase molecules (Figure 3C,D). As a result, it may be assumed that most of
the chemical kinase scaffolds encoded in the latent space of the kinase molecules could be
potentially present within the latent space region populated by the SRC kinase molecules.
In addition, a broad distribution of the latent space for the SRC kinase inhibitors indicated that targeted perturbations in the latent space of the kinase inhibitors targeting other
families could transform these molecules into SRC inhibitors.
2.3. Latent Space and Chemical Feature-Based Kinase Inhibition Likelihood Classifiers
Using Random Forest (RF) architectures, we developed and compared several different
ML classifiers of the kinase inhibition likelihood for the generated molecules. The models were constructed using the training set of kinase molecules from 10 kinase families
combined with a set of GDB-17 small molecules. The binary and multiclass kinase inhibition likelihood classifiers were developed using both the latent space and chemical
feature-based representations of the molecules. The binary classification models considered
all kinase families (except for the target SRC kinase family) together with the dataset of
GDB-17 molecules and assigned them a target value of 0, while the SRC kinase inhibitors
were assigned a target value of 1. The multiclass classification models assigned each of the
considered kinase families a different target variable value, with the goal to identify the
differences between family-specific kinase inhibitors.
The binary latent space classification model was trained using the coordinates of each
molecule in the latent space, where each molecule was represented by a total of 197 feature
variables (196 latent space dimension variables and one classification variable). While
there were distinct clusters of molecules within the latent space, a substantial number
of features for each molecule, when converted to its latent space coordinates, decreased
the overall accuracy (Table S2). The confusion matrix further supported this assessment
showing that the binary latent space model displayed a better performance in classifying
the non-SRC kinase molecules than the SRC kinase molecules (Table S3). Based on this
analysis, we concluded that the overall predictive ability of the latent space-based binary
classifier to identify a newly generated molecule as a potential SRC kinase inhibitor was
not satisfactory. For the chemical feature-based kinase inhibition classifier, we considered a
total of 20 different chemical features for each molecule during training and testing (see
Materials and Methods for a detailed description of chemical features). With the exception
of QED [15], SAS [16], and logP features [17] that are also an integral part of ChemVAE,
an arbitrary selection of other chemical molecular features was utilized to allow for a more
robust classification of the kinase inhibitors. The evaluation metrics and the confusion
matrix for the binary chemical feature-based model displayed an excellent classification
performance (Tables S4 and S5). The sensitivity of the specificity values showed that
the chemical feature binary model accurately distinguished the SRC inhibitors from the
non-SRC kinase molecules in comparison with the latent space binary model.
The latent space-based and chemical feature multiclass models considered the kinase
inhibitors of different protein kinase families as distinct categories by assigning each class
of the kinase inhibitors a different target variable value. The analysis of these classifiers
indicated that the number of classification variables lowered the accuracy of the models
in their predictions of the target values (Tables S6 and S7). Interestingly, it could be seen
that both the multiclass RF model in the latent space (Table S6) and the multiclass chemical
feature-based RF model (Table S7) were less efficient than the binary chemical feature
classifier that was subsequently used in the generative molecular design pipeline (Figure 1)
as the measure of the kinase inhibition likelihood guiding sampling of the latent space.
The receiving operating characteristic (ROC) graph was used to evaluate the performance of the classifier that differentiated the kinase inhibitors from small molecules.
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The AUC of the model showed that the coverage of variation within the dataset was ~97%
and that the model could accurately distinguish both classes of the non-SRC molecules
and the SRC kinase inhibitors with a high level of certainty (Figure 4A). To identify the
primary features in the classification prediction, we also performed the feature importance
analysis (Figure 4B). The top 10 features that contributed the most to the predictive power
of the model included the accessible surface area (labuteASA), molecular weight, Hall–Kier
Alpha descriptor, the number of aromatic rings, aromaticity, the QED score, number of
rotatable bonds, the logP score, the SAS score, and the number of hydrogen bond acceptors
(Figure 4B). Hall–Kier α belongs to the class of topological descriptors that quantify molecular shape similarity within a set of molecules. Interestingly, among the most informative
features of the binary classifier were QED, logP, and SAS scores that are also integral components of the ChemVAE encoder–decoder network. Hence, the results revealed that the SRC
kinase molecules can be differentiated from other kinase molecules using a combination
of fundamental chemical features (the number of aromatic rings, aromaticity, the number
of rotatable bonds, and the number of hydrogen bond acceptors) and drug-like metrics.
11 of 23 that
The precision–recall graph (Figure 4C) highlighted the accuracy of the model, showing
the model starting with a high precision value could eventually trade precision for recall to
reach an equilibrium between the two metrics.
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2.4. Cluster-Based Perturbation Approach for Targeted Exploration of the Latent Space and
Molecular Design
We developed a cluster-based perturbation approach to facilitate targeted sampling
of the latent space. In this model, molecules were first clustered into groups in a non-
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2.4. Cluster-Based Perturbation Approach for Targeted Exploration of the Latent Space and
Molecular Design
We developed a cluster-based perturbation approach to facilitate targeted sampling of
the latent space. In this model, molecules were first clustered into groups in a non-biased
manner allowing molecules with comparable properties to assemble into clusters. Accordingly, it was assumed that the molecules clustered within respective clusters would be
characterized by specific molecular and chemical properties. To transform these molecules,
we then invoked a controllable step of cluster-based perturbation. Using the centroid of each
cluster as the representative of the properties, we navigated every data point in the cluster
closer to the centroid by optimizing a set of parameters. Using this strategy, a cluster-based
perturbation sampling explored the latent space along controllable directions yielding
a diverse set of novel molecules featuring various molecular scaffolds. The generated
molecules were then evaluated using the kinase inhibition likelihood classifier, and when
the output probability was greater than 70%, the respective molecules were designated as
SRC kinase-like inhibitors.
During the cluster-based perturbation stage of the generative design process, 1000 encoded molecules from each of the 10 kinase families were selected and processed through
the pipeline to assess the quality of the predicted molecules and obtain the optimal parameters for the perturbation protocol. These parameters included the number of clusters,
a scaling factor for the centroid-based targeted perturbation, and a noise level for a perturbation step (Figure 5). Using the results of 1000 independent generative experiments with
different values of these parameters, a 3-cluster-based split, a scaling factor of 0.8, and a
noise level of 5.0 were identified as an optimal set of parameters that guaranteed a high
generation yield of valid and novel compounds.
After the perturbation step was executed, the perturbed vector was decoded using
the ChemVAE network. During this stage, the probabilistic neural network performed
500 decoding attempts of the latent variable into a valid SMILES, each time subjecting the
resulting molecules to a validity check via chemical property computations [52] including
an assessment of the QED, logP, and SAS scores. When the network yielded at least
100 valid molecules out of the 500 decoding attempts, the generated molecular output
was subsequently subjected to a comprehensive post-processing analysis in which various
metrics were employed to evaluate the novelty and validity of the chemical transformation
process. We found that together this generative molecular design pipeline produced a
high yield of valid generated molecules while simultaneously morphing the inhibitors of
different kinase families into potential SRC kinase molecules.
To illustrate the output of the generative pipeline, we compiled a list of several
generated SRC-like kinase molecules that originated from the inhibitors of different kinase families. The presented molecules were characterized by the high kinase inhibition
likelihood and a considerable similarity to the existing SRC kinase inhibitors (Figure 6).
We noticed that some of the novel valid molecules with the highest similarity to the SRC
inhibitors were produced starting from the latent space regions of the ABL1 and LCK kinase
inhibitors. It is worth noting that perturbation-based exploration of the latent space was
guided by a feature-based classifier and the kinase inhibition likelihood evaluation that
did not include any direct measurements of similarity to the SRC molecules. A sample of
generated molecules reflected both the diversity of molecular scaffolds and a high degree
of synthetic feasibility that were enabled through a cluster-based perturbation approach
(Figure 6).
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the ChemVAE network. During this stage, the probabilistic neural network performed
500 decoding attempts of the latent variable into a valid SMILES, each time subjecting the
resulting molecules to a validity check via chemical property computations [52] including
an assessment of the QED, logP, and SAS scores. When the network yielded at least 100
valid molecules out of the 500 decoding attempts, the generated molecular output was
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inhibitors. It is worth noting that perturbation-based exploration of the latent space was
guided by a feature-based classifier and the kinase inhibition likelihood evaluation that did
not include any direct measurements of similarity to the SRC molecules. A sample of
generated molecules reflected both the diversity of molecular scaffolds and a high degree of
of 22
synthetic feasibility that were enabled through a cluster-based perturbation12 approach
(Figure 6).
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and the similarity score between the known SRC inhibitor and the generated molecule are shown.

2.5. Kinase Inhibition Likelihood and Similarity Analyses of the Generated Molecules
In the post-processing analysis, we examined whether novel SRC-like molecules
could be generated by the chemical transformation process initiated from the inhibitors
of different kinase families. According to this analysis, the perturbation-based molecular
generation process that started from the inhibitors of LCK and EGFR kinases yielded a
higher percentage of molecules (~19–23%) as compared to the MAPK14 and FLT3 families,
which produced only 5–7% of novel valid molecules (Figure 7A). When only unique and
novel generated molecules were considered, it appeared that starting from the LCK and
MAPK10 kinase inhibitors, the developed model could produce ~20–25% of the total
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To evaluate similarity between the generated molecules and known SRC kinase inhibitors, we also examined the distribution of the generated molecules with the high
Tanimoto similarity coefficient [53]. Our analysis revealed that the generated molecules
originating from LCK inhibitors formed the largest fraction of novel kinase-like compounds
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(~40%) with a high similarity to the SRC kinase inhibitors (Figure 7D). The generated
molecules initiated from the inhibitors of ABL1, MAPK10, MET, and EGFR kinases also
formed a significant fraction of the generated valid molecules with high similarity to the
known SRC inhibitors (Figure 7D). The SRC/ABL and SRC/LCK duality of many kinase
drugs is well recognized, most notably exemplified by dual SRC/ABL drugs dasatinib
and ponatinib. Strikingly, our results reflected these functional observations by revealing
the interconnectivity of the latent spaces for these classes of kinase molecules. According
to our findings, the perturbation-based exploration of the latent space that optimized
sampling along interpretable directions guided by the kinase inhibition likelihood score
could facilitate the generation of novel valid molecules in different areas of the latent space.
To summarize, a combination of the cluster decomposition and perturbation-based
exploration of the latent space allowed for the generation of novel molecules with a high
similarity to the experimentally known SRC kinase inhibitors via chemical transformation
of the kinase inhibitors from different families.
2.6. Drug-like Properties’ Assessment of the Generated Molecules
To evaluate the properties of the generated molecules with a high similarity to the
known SRC inhibitors, we calculated three different drug-like metrics: QED, logP, and SAS
values for the produced molecules, with a specific focus on novel compounds originating
from the inhibitors of ABL1, LCK, and EGFR kinases (Table 1). For comparison, we also
computed these parameters for the known SRC inhibitors. The analysis showed that the
average values of the drug-like parameters for the existing SRC inhibitors and the generated
molecules were similar. Hence, the perturbation-based generation approach yielded novel
valid compounds with a high kinase inhibition likelihood score, high similarity to known
SRC inhibitors, and drug-like properties that were consistent with the corresponding values
seen for the existing SRC inhibitors (Table 1).
Table 1. Drug-Like properties of the generated molecules originating from kinase inhibitors of
different kinase families and exhibiting high similarity with the SRC kinase inhibitors.
Drug-Like Metrics

SRC
Inhibitors

ABL1
Inhibitors

LCK
Inhibitors

EGFR
Inhibitors

Average QED Scores

0.605

0.6742

0.6952

0.6752

Average SAS Score

2.6829

2.9806

2.012

2.8175

Average logP Scores

3.869

3.8989

3.803

3.7687

In addition, we conducted an analysis of the main physicochemical properties of the
generated molecules with a high kinase inhibition likelihood (Table S8). The distribution
of physicochemical descriptors related to the druglikeness of compounds for targeting
protein kinases was recently investigated [54]. According to this study, the number of
hydrogen bond acceptors (HBA) in the kinase molecules is within a range of 3 to 10, while
the number of hydrogen bond donors (HBD) is in the range of 0 to 4 [54]. The average
HBA and HBD numbers for the generated molecules (Table S8) were within the acceptable
range for existing kinase inhibitors meeting the guidelines used for the prioritization of
kinase inhibitors in the drug-like analysis [54]. Similarly, the generated molecules using
our approach also satisfied other criteria for the kinase inhibitors, including the acceptable
molecular weight, and the number of aromatic rings and rotatable bonds (Table S8). Hence,
the pattern and range of major chemical and drug-like parameters for the generated
molecules were consistent with the values featured by the known kinase inhibitors.
We also performed a comparative analysis of the drug-like properties averaged over
generated molecules including QED, SAS, and LogP for classes of produced molecules that
were characterized by a high similarity to the known SRC kinase inhibitors (Figure 8A–C)
as well as by a medium similarity to the SRC inhibitors (Figure 8D–F). Interestingly, we observed a consistent range of acceptable drug-like properties for the generated molecules
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A more complete description of the generated molecules is presented in the Supplementary Materials Information where the following data can be found: (a) the generated
molecules with similarity score, kinase inhibition likelihood score and drug metrics from
the initial experiment of perturbation modeling with only SRC inhibition data; (b) the
generated molecules with similarity score, kinase inhibition likelihood score, and drug
metrics from the molecule transformation perturbation experiments of the kinase inhibitors
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from different families into SRC kinase-like inhibitors; and (c) the generated molecules
from the initial experiments of modifying known SRC kinase inhibitors to design novel
SRC molecules.
All scripts, software, and models used in the development and experiments are available in the GitHub site https://github.com/kassabry/Perturbation_Experiment (accessed
on 27 August 2022). The GitHub site provides detailed documentation and a guide of the
deposited information and software. The deep learning frameworks were supported by
the TensorFlow backend and python tools such as NumPy, SciPy, pandas, and scikitlearn
(Supplementary Materials Information).
3. Materials and Methods
3.1. Datasets of Protein Kinase Inhibitors and Small Molecules
For the training datasets of small molecules, we employed a fraction of the GDB17 database version (GDB database release, 9 August 2021, https://zenodo.org/record/
7041051#.YypEcbTMI2w (accessed on 6 October 2021)) corresponding to small molecules
from a variety of domains, with the following atoms (C, N, O, S, F, Cl, Br, P, I) [50,51].
For the datasets of kinase chemical probes we used (a) ~20,000 known kinase inhibitors
representing 10 major kinase families SRC, ABL1, CSF1R, EGFR, FLT3, KDR, LCK, MAPK10,
MAPK14, and MET that were obtained from ZINC15 database [48] and (b) a dataset of
competitive and allosteric protein kinase inhibitors confirmed by X-ray crystallography
that contained a total of 2899 unique inhibitors including 136 allosteric and 2763 orthosteric
compounds with a total of 231 protein kinases [49]. The kinase inhibitors set included
1883 unique ABL1 kinase inhibitors and 3477 unique SRC kinase inhibitors. By encoding a
set of GDB-17 molecules and a set of kinase inhibitors using ChemVAE framework data,
every molecule was transformed into a 196-dimensional vectorial representation in the
continuous space. The 196-dimensional vectors representing these molecules were then
fed through principal component analysis (PCA) so that we could visualize the continuous
space in two dimensions and analyze different regions (Figure 1).
3.2. Clustering and Perturbation-Based Exploration of the Latent Space and Variational Autoencoder
The perturbation approach was implemented by using a combination of K-means
clustering [55] and perturbation-based exploration of the continuous latent space. Different
cluster-based splits of the latent space were assessed (2-cluster-based split, 3-cluster-based
split, 4-cluster-based split, and 5-cluster-based split) to determine which cluster split gave
the best yield of valid molecules during generation process. Three-cluster-based split of
the latent space yielded the best generational output and was subsequently used in the
perturbation experiments and generation of novel kinase molecules. After implementing
K-means clustering in the latent space, we performed a cluster-based perturbation to each
data point in a cluster using an averaging mechanism. We used the cluster centroid as an
anchoring point for the initial perturbation and applied perturbation to the respective vector
representation of the chemical features and attributes representing the data of the respective
cluster. Utilizing the centroid values invoked targeted alteration to the data within each
cluster, which allowed for generation of new molecules that retained similar chemical and
structural properties to the encoded kinase inhibitors. If each cluster represents a chemical
or structural motif, motif-specific perturbations can be made rather than a “one fits all”
→
→
approach. Assuming that the centroid is ci and one of the datapoints in the cluster is xi we
→
→
take the difference between xi and ci , and multiply that vector by a scaling factor s, where
→

0 ≤ s ≤ 1, giving us our new perturbed vector xi∗ . The targeted perturbation step can be
formulated as
→ →
→
→
xi∗ = xi + s ci − xi
(1)
The scaling factor s acts as a parameter to tune the level of perturbation we want to
achieve. Given that the lower bound of s = 0 corresponds to the original encoding of a
given molecule, while s = 1 provides us with the centroid of the cluster, this parameter
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is initially set to be a threshold of 0.5. By performing perturbation steps and evaluating
kinase inhibition likelihood probabilities, we find that with the scaling factor s < 0.5 the
yield of valid molecules decreases, while a scaling factor s = 0.8 can perturb the initial
molecule gradually towards the centroid of the cluster yielding valid molecules without
losing information of the molecular attributes. The scalar values s = 0.75 − 0.8 allow for
more efficient sampling of the high density areas and valid decoding, producing novel
compounds with the higher success of transformation into the class of potential SRC
kinase inhibitors.
To observe how noise would affect the generation yield of novel compounds, we evaluated six distinct levels of noise, from level 5 to 30 in increments of five. We observed that
a noise level of 5 contributed to a greater generation yield of valid molecules as compared
to noise levels of 10 and above. At a noise level of 10, there was less generation yield than
at a lower noise value. When using noise level 15 and above, the generation yield was
low. Due to the extensive alteration in the continuous latent space, adding random noise to
already perturbed data points could cause additional changes in the chemical and molecular features of the encoded compounds, which results in low density areas of decoding
potential and reduced yield of valid novel molecules. After evaluating and optimizing
every parameter that is involved in the targeted perturbation protocol, we found that a
3-cluster-based split, a scaling factor of 0.8 for the centroid-based perturbation, and a noise
level of 5.0 were the optimal set of parameters to guarantee a sufficiently high generation
yield of valid and novel molecules.
After perturbation step was executed, the perturbed vector was decoded using the
chemical VAE network. We imposed validity constraints on the created molecules by
filtering out any latent locations that had a 0% decode validity. The probabilistic chemical
VAE neural network attempted to decode the latent variable into a valid SMILES string
500 times, each time feeding the molecule into RDKit [52] computations to assess validity.
If the network could yield at least 100 valid molecules out of the 500 decode attempts,
we moved the molecule into the next validity stage. The next validity gate checked the
length of the SMILES string to ensure that no molecule made it through if it had a length
less than 10. The generated molecular output was then run through a post-processing
analysis, where it was evaluated on various metrics to determine validity and success
of transformation.
All scripts, software, and models used in the development and experiments are available in the GitHub site https://github.com/kassabry/Perturbation_Experiment (accessed
on 27 August 2022). The GitHub repository contains the framework and code for molecular
transformations of kinase inhibitors using generative learning methodologies and targeted
perturbation modeling. The GitHub site provides detailed documentation and guide of the
deposited information and software. The deep learning frameworks are supported by the
TensorFlow backend [56] and python tools such as NumPy, SciPy, pandas, and scikitlearn.
The developed software used to conduct PCA analysis and visualization of the latent space
is contained in the perturbation experiment python notebook. The developed software
for the use of the variational autoencoder integrated with the perturbation approach is
contained in the perturbation experiment python notebook. More information on these
files and how to perform the initial setup of the environment can be found in the GitHub
README file.
3.3. Kinase Inhibition Likelihood Classifiers
The Random Forest classification method [57] is used to construct multiclass and
binary kinase inhibition likelihood classifiers in the latent and chemical spaces of small
molecules. The model is initiated with the training set of molecules from all kinase families
as well as GDB-17 molecules. Each molecule within the training set is processed through
RDKit [52] to calculate chemical features. Binary decision trees are created, and the chemical
attributes are used as parameters to determine the most key features in determining the
target variable. Each decision tree makes a prediction on the value of the target variable

Int. J. Mol. Sci. 2022, 23, 11262

18 of 22

and the predictions are then aggregated and averaged to obtain a value between 0 and 1.
If there are more than two classes, the predictions are normalized and then averaged to
maintain a predicted value between 0 and 1. This would ensure that the target value would
still be between 0 and 1 while allowing for multiple classification variables.
For chemical feature-based classifier, 20 chemical features are considered for each
molecule during training and testing: the number of rings, the exact molecular weight,
the number of rotatable bonds, the fraction of carbon Sp3 atoms, the Hall–Kier alpha
value, the Labute ASA value, the number of aliphatic carbocycles, the number of aliphatic
heterocycles, the number of aliphatic rings, the number of amide bonds, the number of
aromatic carbocycles, the number of aromatic heterocycles, the number of aromatic rings,
the number of stereocenters, the number of bridgehead atoms, the number of H-bond
acceptors, the number of H-bond donors, the QED value, the SAS value, and the logP
value. The resulting score in the Random Forest model’s output represents the probability
or likelihood that a molecule can be deemed a kinase inhibitor. Values closer to 0 indicate
that the molecule has a low kinase inhibition likelihood, whereas values closer to 1 indicate
that the molecules have a high kinase inhibition likelihood.
To assess the performance of each model, accuracy, recall, precision and F1 scores
were calculated to measure the performance of classification models. These parameters are
defined as follows
TP + TN
TP
; Precision =
all
TP + FP

(2)

TP
Precision ∗ Recall
; F1 = 2
TP + FN
Precision + Recall

(3)

Accuracy =
Recall =

An F-score is a measure of precision and recall and is often used in binary classification
problems. Precision is defined as the amount of positive samples the model predicts
correctly (true positives) divided by the true positives plus the false positives. Recall
is defined as true positives divided by true positives plus false negatives. The model
performance is evaluated using the receiver operating characteristic area under the curve.
The receiver operating curve (ROC) is a graph where sensitivity is plotted as a function of
1-specificity. The area under the ROC is denoted AUC. A reliable and valid AUC estimate
can be interpreted as the probability that the classifier will assign a higher score to a
randomly chosen positive example than to a randomly chosen negative example.
4. Conclusions
In this work, we proposed an integrated ML approach for controllable molecule
manipulation and an efficient perturbation strategy to improve the steerability and interpretability of the generative models. The results of this study showed that the proposed
method allowed for an efficient exploration of the latent space along interpretable directions
guiding the generation of novel SRC family-specific kinase molecules featuring scaffold
diversity and optimized drug-like biochemical properties. A robust chemical feature-based
machine learning predictor of the kinase inhibition likelihood was developed to aid in the
perturbation-based transformation of small molecules. By combining molecular perturbation design with the kinase inhibition likelihood analysis and similarity assessments,
we demonstrated that the proposed strategy allowed for morphing of the kinase inhibitors
into novel chemical probes of the SRC kinase that exhibit desirable ranges for all included
chemical properties and display a high similarity to the known potent SRC kinase inhibitors.
The central finding of this study revealed that the integration of cluster partitioning and
perturbation-based exploration of the latent space allows for the generation of novel kinase
molecules with a high similarity to the experimentally known SRC kinase inhibitors via
chemical transformation of the kinase inhibitors from different families. Furthermore,
the generated molecular output originating from LCK and ABL1 kinase inhibitors yielded
~40% of novel and valid kinase compounds with kinase inhibition likelihood probability
values (p > 0.75) and high similarity values (Tanimoto coefficient > 0.6).
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Although the proposed perturbation-based approach was robust and showed promise
in the generation of novel valid molecules and the “interpretable transformation” of kinase
molecules towards family-specific kinase probes, there is a significant room for improvement in this approach and related models. Our analysis suggested that one of the important
lines for the improvement of the interpretable and target-oriented molecular design approaches would be retraining and adapting the variational autoencoder to use the wealth
and diversity of the existing kinase inhibitors with different levels of activity, binding
affinity, and selectivity. Since the ChemVAE model is not specifically trained on kinase
molecules, the retraining of the deep neural network using the vast space of kinase inhibitors could potentially lead to a more accurate and granular latent space representation
of the kinase space, thus enabling a more accurate and robust navigation of the kinase
latent landscapes.
An important problem associated with generative learning is the “black box” nature
of neural networks, which often hinders the interpretability of predictions preventing us
from explicitly discerning what specific property or properties are primarily harnessed to
generate output. Despite the ability to generate molecules with desired properties, it is
often difficult to understand the generation process and the chemical rules that govern the
generation process with previous methods. Through assessment of the latent-based and
chemical feature-based binary and multiclass classifiers, we developed a robust probabilistic
evaluator of kinase inhibition likelihood that is specifically tailored to predict novel SRC
kinase inhibitors. The approach leveraged the learned latent space landscapes to achieve
controllable generation by accepting/rejecting sampled molecules based on a robust featureengineered classifier.
Another potential avenue for future improvement would also include the incorporation of three-dimensional features and diverse experimental data on kinase molecules
into VAE models by adding an additional embedding scheme so that the topological and
biological information of molecules can also be embedded and contribute to clustering
and the subsequent perturbation navigation stage of the design process. While exploring
the chemical space with unbiased pretrained autoencoder generative models becomes a
dominant theme in many applications of deep molecular design models, the results of
our study suggested that task-specific manipulation of a biased latent space may be an
important future direction for more effective task-oriented and target-specific autonomous
chemical design models.
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